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ABSTRACT 
Clarithromycin may improve cachexia and survival in non-small cell lung cancer 
(NSCLC), but adequately controlled data are lacking. This study was undertaken 
primarily to inform the feasibility and scale of a phase III trial. Eligible consenting 
patients with stage IV NSCLC and cachexia were to be randomized to receive either 
clarithromycin 250mg twice daily or placebo for eight weeks. Aspects of trial 
feasibility recorded included numbers eligible, approached and recruited, together 
with adherence and completion of treatment and assessments. Over 6 months, none 
of 125 patients identified fulfilled the entry criteria. The commonest reasons for 
ineligibility were the use of an excluded concurrent drug (45, 36%), brain metastases 
(22, 18%), poor performance status (21, 17%) and current chemotherapy (15, 12%). 
A phase III trial of clarithromycin using these entry criteria is not feasible in this 
setting. Other macrolides that have a lower risk of a drug-drug interaction may be 
more practical to pursue. 
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1. Introduction 
 Cachexia is common in lung cancer and is associated with increased 
morbidity and reduced survival [1‒4]. No standard treatment exists and cachexia is a 
major unmet need [5, 6]. Clarithromycin (CLM) is reported to preserve body weight, 
physical independence and increase survival in patients with lung cancer [7, 8]. The 
mechanism may relate to its anti-inflammatory effect as inflammation appears a key 
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contributor to cachexia [9‒11]. CLM also has immunomodulatory and anti-cancer 
effects [12‒14], thought to explain benefit in some haematological cancers [15]. 
 CLM is potentially an inexpensive and widely available cachexia treatment. 
However, no RCTs have been undertaken. Further, CLM interacts with multiple 
drugs, which increases the risk of toxicity; prolongation of the QT interval is a 
particular concern because it predisposes to life-threatening cardiac arrhythmia. 
Thus, we have undertaken a randomized, double-blind, placebo-controlled, feasibility 
study to obtain data to ensure that a phase III study, which takes such safety 
concerns into account, is viable, practical, uses appropriate outcome measures and 
is sufficiently powered. 
 
2. Materials and methods  
For additional details see Supplementary appendix 2. 
2.1. Participants 
 Patients were identified from thoracic oncology clinics at a University hospital. 
Inclusion criteria included age ≥18 years, stage IV non-small cell lung cancer 
(NSCLC), an estimated prognosis of ≥3 months, ≥4 weeks following any 1st or 2nd-
line palliative chemotherapy, along with the presence of cachexia (based on any of: 
weight loss >5% over past 6 months; body mass index <20kg/m2 and weight loss 
>2%; appendicular skeletal muscle index consistent with sarcopenia and weight loss 
>2%), systemic inflammation (C-reactive protein >10mg/L), and adequate hepatic 
and renal function. 
 Exclusion criteria included poor prognostic features (Eastern Cooperative 
Oncology Group (ECOG) performance status ≥3, little or no food intake, weight loss 
>10% in 1 month or >20% in total), active infection requiring antibiotics, inability to 
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accurately measure QT interval, features predisposing to cardiac arrhythmia (QTc 
>450milliseconds (male) or 470milliseconds (female), history of ventricular 
arrhythmia, severe cardiac insufficiency), hypokalaemia, hypomagnesemia, 
concurrent use of drugs with the potential to increase QT interval or enhance other 
toxicities of CLM (see Supplementary appendix 1), use of corticosteroids or 
progestogens within the last 4 weeks, brain metastases and Clostridium difficile 
infection. 
2.2 Study procedures 
 Following written informed consent and confirmation of eligibility, patients 
were to be randomized to receive encapsulated CLM 250mg or matching placebo, 
taken by mouth twice daily for eight weeks. The study received approvals from 
Medicines and Healthcare Regulatory Agency (03057/0063/001-0001), National 
Research Ethics Service Committee East Midlands – Nottingham (14/EM/1281) and 
was on the EU clinical trials register (2014-004873-18). 
2.3. End points and assessments 
 The primary objective was to obtain data on rates of eligibility, recruitment (over 
12 months), data collection and study completion. Secondary objectives were to obtain 
preliminary data on the (a) tolerability of CLM (based on adherence to treatment); (b) 
safety of CLM (based on continual monitoring of toxicity, ECGs to detect prolongation 
of the QT interval) and (c) effect of CLM on patient-centred outcomes of lean body 
mass, physical function, quality of life and systemic inflammation. 
2.4. Statistical analysis 
 A formal power calculation is not appropriate for a feasibility study; the sample 
size reflected the recruitment rate from a large cancer centre, an important aspect of 
feasibility under exploration. Mostly descriptive statistics were used. Appropriate 
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parametric/non-parametric statistics would have been used in an exploratory context 
to compare changes from baseline in patient-centred outcomes. 
 
3. Results 
3.1. Aspects of feasibility 
 Over 6 months, of the 125 patients identified, only one was recruited, but 
failed to meet the criteria for sarcopenia on DEXA scan. As a consequence, the 
decision was taken to close the study. 
 The commonest reasons for ineligibility were the use of an excluded 
concurrent drug (45, 36%), brain metastases (22, 18%), poor performance status 
(21, 17%) and current chemotherapy (15, 12%); for a full list see fig. 1. 
 One patient was receiving two excluded concurrent drugs, the remainder one 
of 17 different kinds, the most common being amlodipine, oxycodone and zopiclone 
(Table 1). 
 
4. Discussion 
 Our failure to recruit suggests that a phase III double-blind, placebo-
controlled study of clarithromycin using these entry criteria is not feasible. None of 
the 125 patients screened met the eligibility criteria. For just under half, this was 
because of brain metastases, poor performance status or concurrent chemotherapy. 
However, the single most common reason, affecting about one-third, was the 
concurrent use of a drug with the potential to interact with CLM to a degree that is 
known to be, or likely to be, clinically significant. This represents an extensive list of 
100 drugs, of which 17 were used by the 45 patients so excluded. It could be argued 
that we were overly cautious, given that such considerations are unlikely to be 
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strictly adhered to in clinical practice. However, this mostly reflects the short-term 
use of CLM as an antimicrobial. In proposing its long-term use as a cachexia 
treatment, we consider additional caution appropriate, particularly given concerns 
about prolongation of the QT interval and the increased risk of ventricular 
arrhythmias and sudden cardiac death observed in patients receiving CLM (and 
other macrolides) [16]. Previous studies of CLM for cancer cachexia predate the 
emergence of these safety concerns [7, 8]. 
 Given the preliminary reports of impressive benefits of CLM in cancer 
cachexia [7, 8], rather than abandon this area completely, the potential exists to 
explore the feasibility of using alternate macrolide antimicrobials. For example, 
although azithromycin has no ‘track record’ in cachexia, it also has 
immunomodulatory properties [17, 18], is used long-term [19, 20], and has a lower 
risk of a drug-drug interaction, such that only 10 of our patients would have been 
excluded on this basis. A formal feasibility study is required to confirm improved 
recruitment and to explore other aspects of the study still untested in our patient 
group. 
 In conclusion, a phase III double-blind, placebo-controlled study of CLM for 
cachexia using these entry criteria is not feasible. The use of other macrolides with a 
lower risk of a drug-drug interaction may be feasible, but requires formal evaluation. 
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Table 1 
Concurrent drugs used resulting in exclusion. 
Drug Number of patients 
Amlodipine 10 
Oxycodone 9 
Zopiclone 4 
Atorvastatin 3 
Clopidogrel 3 
Warfarin 3 
Citalopram 2 
Venlafaxine 2 
Verapamil 2 
Buprenorphine 1 
Colchicine 1 
Diltiazem 1 
Eplerenone 1 
Felodipine 1 
Fentanyl 1 
Gliclazide 1 
Tamsulosin 1 
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Fig. 1. Trial flow diagram. 
